{
  "paper_id": "b5f25901015340a5312e3c9f6b4fc7b1a6744df9",
  "metadata": {
    "title": "The Journal of Infectious Diseases A Highly Immunogenic, Protective, and Safe Adenovirus- Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model",
    "coda_data_split": "dev",
    "coda_paper_id": 1561,
    "coda_has_expert_labels": false,
    "subset": "custom_license"
  },
  "abstract": [
    {
      "original_text": "Background. Infection control measures have played a major role in limiting human/camel-to-human transmission of Middle East respiratory syndrome coronavirus (MERS-CoV); however, development of effective and safe human or camel vaccines is warranted.",
      "sentences": [
        [
          {
            "segment_text": "Background .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Infection control measures have played a major role in limiting human/camel-to-human transmission of Middle East respiratory syndrome coronavirus ( MERS-CoV ) ; however ,",
            "crowd_label": "background"
          },
          {
            "segment_text": "development of effective and safe human or camel vaccines is warranted .",
            "crowd_label": "background"
          }
        ]
      ]
    },
    {
      "original_text": "Methods. We extended and optimized our previous recombinant adenovirus 5 (rAd5)-based vaccine platform characterized by in vivo amplified and CD40-mediated specific responses to generate MERS-CoV S1 subunit-based vaccine. We generated rAd5 constructs expressing CD40-targeted S1 fusion protein (rAd5-S1/F/CD40L), untargeted S1 (rAd5-S1), and Green Fluorescent Protein (rAd5-GFP), and evaluated their efficacy and safety in human dipeptidyl peptidase 4 transgenic (hDPP4 Tg + ) mice.",
      "sentences": [
        [
          {
            "segment_text": "Methods .",
            "crowd_label": "method"
          }
        ],
        [
          {
            "segment_text": "We extended and optimized our previous recombinant adenovirus 5 ( rAd5 ) - based vaccine platform characterized by in vivo amplified and CD40-mediated specific responses to generate MERS-CoV S1 subunit-based vaccine .",
            "crowd_label": "method"
          }
        ],
        [
          {
            "segment_text": "We generated rAd5 constructs expressing CD40-targeted S1 fusion protein ( rAd5-S1 / F/CD40L ) ,",
            "crowd_label": "method"
          },
          {
            "segment_text": "untargeted S1 ( rAd5-S1 ) ,",
            "crowd_label": "method"
          },
          {
            "segment_text": "and Green Fluorescent Protein ( rAd5-GFP ) ,",
            "crowd_label": "method"
          },
          {
            "segment_text": "and evaluated their efficacy and safety in human dipeptidyl peptidase 4 transgenic ( hDPP4 Tg + ) mice .",
            "crowd_label": "method"
          }
        ]
      ]
    },
    {
      "original_text": "Results. Immunization of hDPP4 Tg + mice with a single dose of rAd5-S1/F/CD40L elicited as robust and significant specific immunoglobulin G and neutralizing antibodies as those induced with 2 doses of rAd5-S1. After MERS-CoV challenge, both vaccines conferred complete protection against morbidity and mortality, as evidenced by significantly undetectable/reduced pulmonary viral loads compared to the control group. However, rAd5-S1-but not rAd5-S1/F/CD40L-immunized mice exhibited marked pulmonary perivascular hemorrhage post-MERS-CoV challenge despite the observed protection.",
      "sentences": [
        [
          {
            "segment_text": "Results .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "Immunization of hDPP4 Tg + mice with a single dose of rAd5-S1 / F/CD40L elicited as robust and significant specific immunoglobulin G and neutralizing antibodies as those induced with 2 doses of rAd5-S1 .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "After MERS-CoV challenge , both vaccines conferred complete protection against morbidity and mortality ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "as evidenced by significantly undetectable/reduced pulmonary viral loads compared to the control group .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "However , rAd5-S1-but not rAd5-S1 / F/CD40L-immunized mice exhibited marked pulmonary perivascular hemorrhage post-MERS-CoV challenge despite the observed protection .",
            "crowd_label": "finding"
          }
        ]
      ]
    },
    {
      "original_text": "Conclusions. Incorporation of CD40L into rAd5-based MERS-CoV S1 vaccine targeting molecule and molecular adjuvants not only enhances immunogenicity and efficacy but also prevents inadvertent pulmonary pathology after viral challenge, thereby offering a promising strategy to enhance safety and potency of vaccines.",
      "sentences": [
        [
          {
            "segment_text": "Conclusions .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "Incorporation of CD40L into rAd5-based MERS-CoV S1 vaccine targeting molecule and molecular adjuvants not only enhances immunogenicity and efficacy but also prevents inadvertent pulmonary pathology after viral challenge ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "thereby offering a promising strategy to enhance safety and potency of vaccines .",
            "crowd_label": "finding"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "4",
    "sentence_num": "11",
    "segment_num": "17",
    "token_num": "248"
  }
}